Literature DB >> 15792261

Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions.

Dante Antonelli1, Shaul Atar, Nahum A Freedberg, Tiberio Rosenfeld.   

Abstract

BACKGROUND: Torsade de pointes is rarely associated with chronic amiodarone treatment, despite the effect of amiodarone on QT interval prolongation.
OBJECTIVE: To identify risk factors and associated conditions that may cause TdP in patients on chronic amiodarone treatment.
METHODS: We reviewed the data of six consecutive patients on chronic amiodarone treatment who were admitted to the intensive cardiac care unit due to syncope and TdP.
RESULTS: The patients' median age was 73.5 years, and five were women. Concomitantly, loratadine was given to two patients and trazodone to one patient. Associated and attributing conditions to the development of TdP were hypokalemia in three patients, drug-induced bradycardia in one and reduced left ventricular function in four.
CONCLUSIONS: TdP associated with chronic amiodarone treatment may occur when amiodarone is co-administered with drugs that may potentially prolong QT interval. Additional risk factors for amiodarone-associated TdP include female gender, hypokalemia, reduced left ventricular function and bradycardia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15792261

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


  8 in total

Review 1.  Assessing QT interval prolongation and its associated risks with antipsychotics.

Authors:  Jimmi Nielsen; Claus Graff; Jørgen K Kanters; Egon Toft; David Taylor; Jonathan M Meyer
Journal:  CNS Drugs       Date:  2011-06-01       Impact factor: 5.749

2.  Falling between the cracks: a case of amiodarone toxicity.

Authors:  Constanze Mackenzie; Jaffer Syed; P Timothy Pollak; Gideon Koren
Journal:  CMAJ       Date:  2011-07-11       Impact factor: 8.262

Review 3.  Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly.

Authors:  W Victor R Vieweg; Mark A Wood; Antony Fernandez; Mary Beatty-Brooks; Mehrul Hasnain; Anand K Pandurangi
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

4.  Potential drug-drug interactions in prescriptions dispensed in community pharmacies in Greece.

Authors:  Anna Chatsisvili; Ioakeim Sapounidis; Georgia Pavlidou; Eudoxia Zoumpouridou; Vasileios-Alexandros Karakousis; Marios Spanakis; Lefteris Teperikidis; Ioannis Niopas
Journal:  Pharm World Sci       Date:  2010-01-14

5.  Sex differences in the relationship between amiodarone use and the need for permanent pacing in patients with atrial fibrillation.

Authors:  Vidal Essebag; Matthew R Reynolds; Tom Hadjis; Robert Lemery; Brian Olshansky; Alfred E Buxton; Mark E Josephson; Peter Zimetbaum
Journal:  Arch Intern Med       Date:  2007 Aug 13-27

Review 6.  Withdrawal of prenylamine: perspectives on pharmacological, clinical and regulatory outcomes following the first QT-related casualty.

Authors:  Rashmi R Shah; Peter D Stonier
Journal:  Ther Adv Drug Saf       Date:  2018-06-18

7.  Pro-arrhythmic potential of oral antihistamines (H1): combining adverse event reports with drug utilization data across Europe.

Authors:  Elisabetta Poluzzi; Emanuel Raschi; Brian Godman; Ariola Koci; Ugo Moretti; Marija Kalaba; Bjorn Wettermark; Miriam Sturkenboom; Fabrizio De Ponti
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

Review 8.  Adverse reactions of Amiodarone.

Authors:  Ruben Ml Colunga Biancatelli; Viviana Congedo; Leonardo Calvosa; Marco Ciacciarelli; Alessandro Polidoro; Luigi Iuliano
Journal:  J Geriatr Cardiol       Date:  2019-07       Impact factor: 3.327

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.